Ristocetin-Induced Thrombocytopenia: Site and Mechanism of Action

AMA Arch Intern Med. 1960;105(1):83-89. doi:10.1001/archinte.1960.00270130099012.
Text Size: A A A
Published online

Ristocetin is a new antimicrobial agent consisting of two antibiotics, ristocetin A and B. These components have been separated from the fermentation broth of the actinomycete species Nocardia lurida. Advantages of this drug include the lack of development of resistant organisms and an absence of cross-resistance with other antibiotics. Several investigators have demonstrated the merit of ristocetin in problems of severe staphylococcal and enterococcal infections.1-4

In previous publications5,6 the development of thrombocytopenia in four patients during ristocetin therapy was noted. Platelet depression was related to high doses of ristocetin and could be reversed by discontinuing or reducing the dose. Individuals with renal insufficiency were more susceptible to thrombocytopenia due to drug accumulation.

The purpose of this publication is to report on the subsequent clinical experience and laboratory findings, and to relate these observations to the mechanism and site of action of ristocetin-induced thrombocyto-penia. Five patients have been treated with ristocetin


Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview





Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 57

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.